Artivion (NYSE:AORT) Price Target Lowered to $30.00 at Stifel Nicolaus

Artivion (NYSE:AORT) had its target price decreased by research analysts at Stifel Nicolaus from $33.00 to $30.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 7.53% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Oppenheimer boosted their price target on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Finally, Needham & Company LLC dropped their price objective on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $31.40.

Artivion Trading Down 1.3 %

NYSE:AORT opened at $27.90 on Tuesday. The firm has a 50-day simple moving average of $29.75 and a 200-day simple moving average of $27.83. Artivion has a one year low of $18.38 and a one year high of $32.33. The firm has a market cap of $1.17 billion, a P/E ratio of -1,394.90 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Insiders Place Their Bets

In other Artivion news, SVP Jean F. Holloway sold 8,070 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the sale, the senior vice president now owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the transaction, the vice president now owns 33,503 shares in the company, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,017 shares of company stock valued at $600,007. 8.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Artivion

Several hedge funds have recently made changes to their positions in the company. Quarry LP grew its stake in Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after purchasing an additional 820 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the period. R Squared Ltd purchased a new stake in Artivion in the fourth quarter valued at approximately $39,000. Arcadia Investment Management Corp MI acquired a new position in Artivion in the 4th quarter worth approximately $43,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Artivion during the 4th quarter worth approximately $64,000. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.